Dana Point Pharmaceuticals Inc.

Tokai Pharmaceuticals Initiates ARMOR Clinical Development Program for TOK-001; First Ever Multi-Target Investigational Drug for Prostate Cancer.
Cancer Weekly; 11/24/2009; 2157 words; Tokai Pharmaceuticals, Inc., a biopharmaceutical...S (see also Tokai Pharmaceuticals). "TOK-001 delivers...the only option at this point that has been shown to...Genitourinary Oncology at the Dana-Farber Cancer Institute...

Other News To Note.
BIOWORLD Today; 11/3/2009; 1665 words; ...collaboration with Dana Farber Cancer Center...Lake. ChemGenex Pharmaceuticals Ltd., of Melbourne...services of MolecularMD Inc., of Menlo Park...patients with the T315I point mutation also fail...Columbia, and BioSeek Inc., of Burlingame...York-based Pfizer Inc., for $16.6...

Constellation Pharmaceuticals Appoints Renowned Cancer Biologist Edward E. Harlow, Jr., Ph.D. as Company's CSO.
Cancer Weekly; 9/22/2009; 1619 words; ...Pharmaceuticals, Inc. announced...Pharmaceuticals, Inc.). Dr. Harlow...Director of the Dana-Farber/Harvard...this pivotal point as we grow our...Constellation Pharmaceuticals. "He has an...established pharmaceutical companies...biotechnology and pharmaceutical ...

News and FDA Updates for Obagi (Nasdaq:OMPI), Spectrum (Nasdaq:SPPI), Positron (OTC:POSC), La Jolla (Nasdaq:LJPC).
M2 Presswire; 9/21/2009; 1070 words; ...Medical Products, Inc. (Nasdaq:OMPI...09/09, Spectrum Pharmaceuticals, Inc. (Nasdaq:SPPI...Fall Conference in Dana Point, California September...09/09, La Jolla Pharmaceutical Company (Nasdaq...

Constellation Pharmaceuticals Appoints Renowned Cancer Biologist Edward E. Harlow, Jr., Ph.D. as Company's CSO; Company Leading Emerging Field of Epigenetics-.
M2 Presswire; 9/9/2009; 1359 words; ...Pharmaceuticals, Inc.: Constellation...Pharmaceuticals, Inc. today announced...Director of the Dana-Farber/Harvard...this pivotal point as we grow our...Constellation Pharmaceuticals. "He has an...established pharmaceutical companies...biotechnology and ...